. @avacta has received a $2M licensing renewal payment from LG Chem #LifeSciences as it moves towards Investigational New #Drug (IND) enabling studies for the Affimer PD-L1 antagonist #therapeutic programme.

More here:

. @avacta today announced the second dose escalation in the Phase I #clinicaltrial of AVA6000, a novel form of #doxorubicin modified with Avacta’s pre|CISION FAP-activated delivery platform to improve its safety and therapeutic index.

Learn more here:

Our MD, Lorna Cuddon, is at @themilnerinst’s #MilnerSymp22 today, in-person. Following interesting sessions on novel #drug targets and #therapeutic #research, we’re looking forward to connecting with fellow attendees at the #networking lunch and drinks reception this evening.